Dr. Wang co-founded AnHeart Therapeutics with other two co-founders in 2018. Before AnHeart, he severed as Head of Global Biostatistics, Epi and Medical Writing at Merck Serono, China.  Before Merck Serono, he served various leadership role in global clinical development and medical research at BMS, Wyeth/Pfizer, The Medicines Company, and Merck & Co. His drug development experience includes therapeutic areas such as oncology, cardiovascular, neuroscience, immunology, and hematology. He has played a critical role in two successful NDAs for the US market and other worldwide markets. Besides his many interactions with FDA and EMA, he has also played a critical role in communications with PMDA and NMPA for label extension submissions.

Dr. Wang serves as a global expert for two NMPA/CDE ICH working groups.

Dr. Wang earned BS from the University of Science and Technology of China and PhD from Iowa State of University.